NHLBI
Research and Policy Update PA-02-011: Extension of Bioengineering Research Grant (BRG) Program Announcement (NOT-EB-05-005) PA-05-103: Pilot and Feasibility Program Related to the Kidney For
additional initiatives, please visit the following Web page: NIH
Public Access Policy Exploring the Mysteries of Actin and Myosin: A Symposium to Honor Edward D. Korn, October 17, 2005 From Genome to Disease II: A Symposium of High Throughput Biology -- NHLBI Programs for Genomic Applications, July 19-20, 2005 National
Heart, Lung, and Blood Advisory Council, June 16, 2005 Cardiomyopathies in Children with Rare Diseases, Working Group Executive Summary, March 14, 2005 National Heart, Lung, and Blood Advisory Council Meeting Minutes, February 10, 2005 Assessment and Treatment of Depression in Patients with Cardiovascular Disease, Working Group Report, August 10-11, 2004 Translation of Cardiovascular Cell Based Therapies, Working Group Interim Summary Report, August 5-6, 2004 For more information
on past meetings, please visit the following Web page:
Deputy Director: The NHLBI is seeking exceptional candidates to provide leadership with the Director for a national research program in diseases of the heart, blood vessels, lung, and blood; blood resources; and sleep disorders, and administrative management of the NIH Women’s Health Initiative. Special Assistant for Clinical Research to the Director: The NHLBI is seeking exceptional candidates to advise the Director and other senior Institute staff on programmatic issues related to the design, organization, conduct, and analysis of clinical research on heart, lung, blood, and sleep disorders. Note: There
are often changes and additions to this list, for the most current information,
please visit the NHLBI Jobs Opportunities
page Genetically Altered Animal Models Related to Heart, Lung, Blood, or Sleep (Database Updated) Annual Report of the Trans-NIH Sleep Research Coordinating Committee, FY 2004 Limited Access Data Set: The Beta-Blocker Evaluation of Survival TrialThe Beta-Blocker Evaluation of Survival Trial (BEST) was designed to determine whether bucindolol hydrochloride—a nonselective beta-adrenergic blocker and mild vasodilator—would reduce the rate of death from any cause among patients with advanced heart failure and to assess its effects in various subgroups defined by ethnic background and demographic criteria—specifically women and members of minority groups. An Archive of the current and past issues is available on the NHLBI Web site. Two ways to unsubscribe:
|